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Abstract
The incidence and mortality of prostate cancer (PCa)
vary greatly in different geographic regions, for which
lifestyle factors, such as dietary fat intake, have been
implicated. Human 15-lipoxygenase-1 (h15-LO-1), which
metabolizes polyunsaturated fatty acids, is a highly
regulated, tissue-specific, lipid-peroxidating enzyme
that functions in physiological membrane remodeling
and in the pathogenesis of atherosclerosis, inflam-
mation, and carcinogenesis. We have shown that aber-
rant overexpression of 15-LO-1 occurs in human PCa,
particularly high-grade PCa, and in high-grade prostatic
intraepithelial neoplasia (HGPIN), and that the murine
orthologue is increased in SV40-based genetically en-
gineered mouse (GEM) models of PCa, such as LADY
and TRansgenic Adenocarcinoma of Mouse Prostate.
To further define the role of 15-LO-1 in prostate carcino-
genesis, we established a novel GEM model with
targeted overexpression of h15-LO-1 in the prostate
[human fifteen lipoxygenase-1 in mouse prostate
(FLiMP)]. We used a Cre- mediated and a loxP-mediated
recombination strategy to target h15-LO-1 specifically to
the prostate of C57BL/6 mice. Wild-type (wt), FLiMP+/,
and FLiMP+/+ mice aged 7 to 21, 24 to 28, and 35 weeks
were characterized by histopathology, immuno-
histochemistry (IHC), and DNA/RNA and enzyme analy-
ses. Compared towtmice, h15-LO-1 enzyme activitywas
increased similarly in both homozygous FLiMP+/+ and
hemizygous FLiMP+/ prostates. Dorsolateral and ven-
tral prostates of FLiMP mice showed focal and pro-
gressive epithelial hyperplasia with nuclear atypia,
indicative of the definition of mouse prostatic intra-
epithelial neoplasia (mPIN) according to the National
Cancer Institute. These foci showed increased prolifer-
ation by Ki-67 IHC. No progression to invasive PCa was
noted up to 35 weeks. By IHC, h15-LO-1 expression was
limited to luminal epithelial cells, with increased ex-
pression in mPIN foci (similar to human HGPIN). In sum-
mary, targeted overexpression of h15-LO-1 (a gene
overexpressed in human PCa and HGPIN) to mouse
prostate is sufficient to promote epithelial proliferation
and mPIN development. These results support 15-LO-1
as having a role in prostate tumor initiation and as an
early target for dietary or other prevention strategies. The
FLiMP mouse model should also be useful in crosses
with other GEMmodels to further define the combinations
of molecular alterations necessary for PCa progression.
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Introduction
Cancer mortality is principally associated with tumor invasion
and dissemination. Therefore, understanding the processes by
which localized carcinoma evolves into invasive carcinoma will
likely have therapeutic implications. In prostate cancer (PCa),
disease progression is thought to proceed through multiple
steps, from prostatic intraepithelial neoplasia (PIN) to locally
invasive carcinoma to metastatic disease. Progression through
various stages of tumorigenesis presumably requires altera-
tions in the gene expression of both tumor oncogenes, and
tumor-suppressor and mutator genes in initiated cells. Ulti-
mately, these genetic lesions alter cancer cell phenotype by
modifying global gene expression patterns.
We demonstrated increased expression of an N-6 fatty acid
linoleic acid (LA)–metabolizing enzyme, 15-lipoxygenase-1
(15-LO-1, ALOX15), in prostate tumor tissues compared
with normal adjacent prostate tissues [1,2]. Further work from
our laboratory and others [3–8] suggests that the metab-
olites of polyunsaturated fatty acids directly impact prostate
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tumorigenesis and that the ability to do so depends on
both dietary intake and metabolic enzyme expression [9].
Although arachidonic acid can also act as a substrate for
15-LO-1, yielding the anti-inflammatory and proapoptotic
metabolite 15-(S)-hydroxyeicosatetraenoic acid, the 15-LO-
1 enzyme greatly prefers LA. 15-LO-1 metabolizes LA to
13-(S)-hydroxyoctadecadienoic acid [13-(S)-HODE], which
can regulate cell growth, differentiation, and vascular homeo-
stasis [10–19]. Our data [10–12,20] and other reports
[21–24] indicate that 13-(S)-HODE is mitogenic and thus
enhances cellular proliferation [11,13–19]. Indeed, inhibition
of 15-LO-1 enzyme activity causes apoptosis in the PCa cell
line PC3 [11,20].
Several of our findings support a possible role for 15-LO-1
in PCa tumorigenesis: 1) expression of 15-LO-1, the gene
of which maps to human 17p13.3, was upregulated by a mu-
tant p53, but not by a wt p53 [25]; 2) the expression of 15-
LO-1 and mutant p53 correlated with each other and with
Gleason grade in prostate tumor epithelium [1]; 3) injection of
athymic mice with PC3 cells overexpressing 15-LO-1 re-
sulted in the development of aggressive tumors [11]; 4) ex-
pression of 15-LO-1 correlated with the upregulation and
activation of the insulin-like growth factor-1 receptor in PCa
cells [12]; and 5) analysis of the TARP-2 multitumor human
tissue array from the National Cancer Institute (NCI) revealed
an increased expression of 15-LO-1 in PCa, lung cancer,
breast cancer, melanoma, and colonic adenocarcinoma, com-
pared with normal controls [26]. Recently, we demonstrated
that methylation of a single CpG within the second CpG island
of an 15-LO-1 promoter is frequently present in individuals
with high-grade prostatic intraepithelial neoplasia (HGPIN)
and PCa [27]. Our study identified a new role for epigenetic
phenomenon in PCa wherein hypermethylation of the 15-
LO-1 promoter leads to the upregulation of 15-LO-1 expres-
sion and enzyme activity, which contributes to PCa initiation
and progression.
Conversely, a decrease in 15-LO-1 activity is observed in
colon and esophageal cancers [28–30]. Although many
cancers in humans arise from germline mutations occurring
in all cells, the majority of cancers in humans arise sponta-
neously from epigenetic aberrations, such as methylation,
that occur in genomic DNA of individual cells. This phenom-
enon (not genetic mutations) plays am essential role in early
PCa development [31]. Therefore, the development of model
systems that allow us to mimic this type of spontaneous
disease in mice while still maintaining control over the me-
tabolismevent is critical to our understanding of themolecular
mechanisms leading to chemopreventive recommendations
in slowing the progression of human PCa. This is well
recognized within the field [Mouse Models of Human Cancer
Consortium (MMHCC) members] [32].
To more closely approximate the pattern of the somatic
overexpression of 15-LO-1 observed in human prostate neo-
plasia (PIN) and tumors, we generated transgenic mice using
a ‘‘flox–stop’’ approach. This allows for tissue-specific ex-
pression of transgene in selected cell types based on the
expression pattern of Cre recombinase enzyme in animals.
Tissue-specific Cre recombinase activity can be accom-
plished by breeding to Cre-transgenic mice (as performed
here) or by other methods such as viral infection. This latter
approach can be used to induce transgene expression in a
subset of cells within a given tissue, to better mimic spon-
taneous human disease [33]. To develop the model, we
generated transgenic mice expressing the construct CAG–
loxP–CAT–loxP–h15-LO-1 in which 15-LO-1 expression is
blocked but chloramphenicol acetyl-transferase (CAT) ex-
pression is driven by a ubiquitous CAG promoter. These
animals are henceforth called REAGENT mice. These ani-
mals were then crossed to transgenic mice that express Cre
recombinase under a prostate-specific androgen-responsive
probasin (Pb) promoter [34]. This leads to the expression
of Cre recombinase in prostate epithelia at puberty, deletion
of CAT reporter stop cassette, and subsequent 15-LO-1
expression in all prostatic epithelial cells. The resulting con-
ditional transgenic mouse is called fifteen lipoxygenase-1 in
mouse prostate (FLiMP) and expresses human 15-lipoxyge-
nase-1 (h15-LO-1) only in mature prostate. 15-LO-1 ex-
pression in these animals predisposes the animals to the
development of lesions in an age-dependent fashion that
closely resembles human PIN. Our findings confirm that






tion The transgene design is as follows. A strong, constitu-
tive promoter, CAG (consisting of a cytomegalovirus enhancer
and a chicken b-actin promoter) [35], is linked to two genetic
elements: a CAT reporter gene and human 15-LO-1 cDNA.
TheCAT reporter gene lies upstream of 15-LO-1 cDNA and is
flanked by two loxP sites, which are recognition sites for the
bacterial enzyme Cre recombinase. In the absence of further
genetic manipulation, the CAG promoter drives the expres-
sion of the CAT reporter gene but stop codons at the 3V end of
the reporter, terminating transcription before the initiation of
human 15-LO-1 cDNA.
The CAG–loxP–CAT–loxP vector was a kind gift from
Dr. Pierre Vassalli (Department of Pathology, University of
Geneva, Geneva, Switzerland). The pcDNA3.1 vector con-
taining the 2.7-kb full-length human 15-LO-1 cDNA was
excised with EcoRI, and the 15-LO-1 cDNA fragment blunt
end was cloned by T4 DNA ligase (New England Bio-
laboratories, Inc., Ipswich, MA) into a predigested CAG
vector with EcoRV. EcoRV digestion removed the cloned
lacZ gene. This 10-kb CAGloxPCAT–STOPloxPh15-LO-1
construct (Figure 1A) was sequence-verified, purified by
electrophoresis, eluted with NACS PREPAC (Gibco BRL,
Grand Island, NY), and used for microinjection. The plasmid
CAGloxPCAT–STOPloxPh15-LO-1 was purified with NACS
PREPAC, suspended in 1 mM Tris–HCl (pH 7.5)/0.1 mM
EDTA at 5 ng/ml, and used for microinjection. Transgenic
mice were produced as described below.
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Generation of transgenic mice Transgenic CAGloxPCAT–
STOPloxPh15-LO-1 mice (REAGENT) were produced by
pronuclear microinjection of day-0.5 embryos from a
C57BL/6 strain (NCI Charles River Laboratories,Wilmington,
MA) using standard techniques [36]. All potential transgene
founders were tailed at 10 to 12 days of age and given a
unique identification number using either a toe tattoo or a
toe clip system. Amicrotattooer with a sterile 30-gauge hypo-
dermic needle was used to inject tattoo ink into the toe pads
of individual mice for identification with a standard identifica-
tion chart (Ketchum Manufacturing, Inc., Brockville, Ontario,
Canada). Genomic DNA was isolated from the tails of po-
tential founder mice and analyzed for the presence of the
CAG–loxP–CAT– loxP–h15-LO-1 transgene using poly-
merase chain reaction (PCR), with primers located within
h15-LO-1 cDNA. The forward primer is located in exon 12 (5V-
GTGGAAGGAATCGTGAGTCTCCACT-3V) and the reverse
primer is located in exon 14 (5V-GTCTGCCCAGCTGCAGT-
GATGGA-3V) of the 15-LO-1 gene. The size of the amplified
15-LO-1 transgene is 388 bp, whereas the size of the human
genomic 15-LO-1 DNA (used as a positive control) is 1098 bp
(Figure 1B). The primers do not amplify rat or murine 12/
15-LO gene. The reaction conditions for the PCR were as
follows: 95jC/10 minutes, 94jC/30 seconds, 63jC/30 sec-
onds, and 72jC/30 seconds for 35 cycles, with a final ex-
tension cycle at 72jC for 5 minutes. PCR products were
analyzed by gel electrophoresis and visualized with a BioRad
gel capture system (BioRad, Inc., Hercules, CA).
Initial characterization of founder lines Three CAGloxP-
CAT–STOPloxPh15-LO-1 (REAGENT) transgenic founder
lines were identified, as shown in Figure 2, and designated
as lines 1857, 1863, and 1868. All three transgenic founder
lines were bred to C57BL/6 wt mice (NCI Charles River Labo-
ratories) and were characterized for germline transmission,
tissue tropism, and level of CATexpression. In addition, mul-
tiple tissues from all lines were tested for basal h15-LO-1
expression to ensure that there was no aberrant back-
ground expression of 15-LO-1. All three lines demonstrated
high levels of CAT expression in all tissues tested, without
any background expression of h15-LO-1 (Figure 2; data
not shown).
CAT assay Transgenic mice from either the three
REAGENT lines (1857, 1863, and 1868) or the 1868Pb-
Cre FLiMP line (n = 4) were sacrificed at 2 months of age.
Tissues were collected and used immediately, or frozen
and stored at 80jC. CAT assays were performed as de-
scribed before [37]. Briefly, each tissue was individually
homogenized and heated at 65jC for 8 minutes, and the
supernatant was used for CATand protein determination as-
says. The concentration of soluble protein was determined
by BioRad protein assay. The percentage of [14C]chloram-
phenicol converted to acetylated forms was determined
either by densitometric scanning of autoradiograms using
a Phosphorimager (Storm860) with IMAGEQUANT ver-
sion 5.1 software or by scraping of individual spots from
thin-layer chromatography (TLC) and counting in a scintilla-
tion counter. CAT activities were expressed as picomoles of
acetyl chloramphenicol generated per minute per milligram
of protein, after subtracting the background for each tissue
from control mice that do not express the CAT gene. Specific
activity was calculated as picomoles of product per milligram
of protein per minute.
Generation and characterization of FLiMP transgenic mouse
model The 1868 transgenic line (REAGENT-3) identified
above was crossed to Pb-Cre4 mice to generate offspring
that carry both transgenes. In Pb-Cre4 mice, Cre expression
is prostate-specific, except for a few scattered areas in the
gonads and in the stroma of the seminal vesicle. Expression
differs between lobes, with expression being highest in the
lateral lobe, followed by the ventral lobe, the dorsal lobe, and
the anterior lobe, which have lower levels of expression.
Resultant pups were PCR-screened for the presence of the
CAGloxPCAT–STOPloxPh15-LO-1 transgene, as described
above. Mice were also screened for Pb-Cre transgene using
a PCR genotyping strategy, as previously described [34].
Male double transgenic mice [hereafter referred to as
FLiMP+/+ (homozygous) and FLiMP+/ (hemizygous) mice]
from the 1868 line were characterized at 8 to 10 weeks of
age for the extent of CRE-mediated deletion of the CAT
reporter gene (by CAT analysis, as described above), and
resultant h15-LO-1 expression and activity. FLiMP mice
demonstrated efficient deletion of the reporter CAT gene
and expression of h15-LO-1.
RNA preparation and amplification Sample RNA from dis-
sected dorsal, lateral, anterior, and ventral prostates, each
from three transgenic C57BL/6, FLiMP+/, and FLiMP+/+
mice at 10, 20, and 30 weeks of age, were pooled and
compared to control RNA similarly extracted from age-
matched nontransgenic C57BL/6 littermates. Dissected
prostate tissues were immediately immersed in RNAlater
(Ambion, Inc., Austin, TX). Total RNA was then purified with
DNase I using RNeasy kit (Qiagen, Valencia, CA), following
the manufacturer’s protocol. RNA was quantified by spec-
trophotometry (Eppendorf, Hamburg, Germany), and its in-
tegrity was assured by analysis using a BioRad Experion
RNA analyzer chip (BioRad, Inc.). Real-time quantitative re-
verse transcription–polymerase chain reaction (qRT-PCR)
was performed in a 25-ml mixture containing first-strand
cDNA synthesized using 1 mg of total RNA (DNase-treated)
and a reverse transcriptase reaction mixture. A 92-bp region
of mouse b-actin cDNA using primers 5V-CCTGGCACC-
CAGCACAAT-3V and 5V-GCCGATCCACACGGAGTACT-3V
was amplified at 95jC/10 minutes (95jC/30 seconds and
59jC/60 seconds) for 40 cycles using 1 SYBR Green and
buffer (PE Applied Biosystems, Foster City, CA), 4 mM
MgCl2, 0.2 mM of each primer (b-actin and 15-LO-1), 0.2 mM
dNTP mixture, and 0.025 U of AmpliTaq Gold thermostable
DNA polymerase (Applied Biosystems, Foster City, CA). A
192-bp region of h15-LO-1 using 15-LO-1 primers 5V-GACC-
GAGGGTTTCCTGTCTC-3V and 5V-TGTCTCCAGCGTTG-
CATCC-3V was similarly amplified (but without SYBR Green)
at 95jC/3 minutes (95jC/30 seconds and 58jC/60 seconds)
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for 40 cycles and quantified by a TaqMan probe 5V-5HEX-
CAGGCTCGGGACCAGGTTTGCCAG-BHQ2a-5HEX-3V.
Real-time quantitations were performed using the iQ5 Real-
Time PCR Detection System (BioRad, Inc.). Fluorescence
threshold was calculated using system software. Optimization
experiments showed that PCRs (performed in triplicate) for b-
actin were highly reproducible, with a low intra-assay coeffi-
cient of variation (0.5%).
Determination of 15-LO-1 expression/activity by enzyme-
linked immunosorbent assay (ELISA) Tomeasure 15-LO-1
activity, the level of the LA metabolite 13-HODE in tissues
was examined using commercially available ELISA plates
(Oxford Biomedical Research, Inc., Oxford, MI). Prostate tis-
sues from transgenic and wt nontransgenic littermate con-
trols were homogenized in 600 ml of buffer containing 50 mM
Tris–HCl (pH 7.4), 25 mM LA, and 5 mM CaCl2. In all buffers,
protease inhibitors were added just before use: 1 mM phenyl-
methylsulfonyl fluoride, 1 mM benzamidine, 10 mg/ml aproti-
nin, 10 mg/ml leupeptin, and 1 mg/ml pepstatin A. After
incubation, 0.3 mg of sodium borohydride was added, and
the mixture was kept on ice for 15 minutes. This mixture was
then acidified with HCl (pH 3.0). The sample was extracted in
2 ml of ethyl ether, the solvent was evaporated, and the dried
material was dissolved in 50 ml of methanol/water (3:1)
solvent. Concentrations of 13-(S)-HODE were represented
as micrograms per milliliter per gram of tissue after normal-
izing for the endogenous 12/15-LO activity of proteins in
samples of transgenic wt littermate controls.
Preparation and analyses of tissues for prostate histopa-
thology Individual 1868 FLiMP+/ and FLiMP+/+ male mice
were sacrificed from 6 to 35 weeks of age and examined for
gross organ abnormalities. The urogenital tract was removed
intact, and the tissues were dissected to remove the bladder
and associated fats. The tissues (including all prostate lobes,
and the seminal vesicles) were fixed in buffered formalin.
The urogenital tract, including the bladder, seminal vesicles,
prostate (dissected dorsolateral, ventral, and anterior lobes),
testes, and epididymides, were removed on necropsy en bloc
and prepared for pathological evaluation, as described below.
For histology, the prostate was treated with an acid alcohol
solution, as described by Folkvord et al. [38]. Fixed tissues
were embedded in paraffin, and sections were stained with
hematoxylin and eosin (H&E) [39]. Prostate lesions were
assessed according to the consensus classification of the
MMHCC (October 2000; Bar Harbor,ME) by two independent
pathologists (A.V.P. and S.B.S.) who were blinded to the
genotypes of the animals [32].
Mice were sacrificed at different age time points (as de-
scribed above), tissues were harvested, and tissue sections
were prepared for immunohistochemistry (IHC). The follow-
ing tissues were analyzed wherever indicated: prostate (ante-
rior, dorsal, lateral, and ventral lobes), regional lymph nodes
(lateral iliac and aortic lumbar), liver, lungs, spleen, kidneys,
bone (lumbar vertebra), adrenal glands, brain, salivary glands
(submandibular and parotid), submandibular lymph nodes,
bulbourethral glands, and grossly remarkable skin and sub-
cutaneous tissues. Tissue sections obtained from the mice
were deparaffinized and dehydrated, endogenous peroxidase
activity was blocked, and sections were treated with normal
serum to bind nonspecific sites. The sections were then
incubated with primary antibodies or with nonimmune mouse
IgG. In this study, rabbit polyclonal anti–Ki-67 antibody was
used to study the proliferation index. Secondary IgGs of
appropriate species specificity were used. Sections were de-
veloped with 3,3-diaminobenzidine (brown). Sections were
also counterstained for H&E staining. Control sections were
processed in parallel with mouse or rabbit nonimmune IgGs at
the same concentration as that with primary antibodies. As
generated in this study, polyclonal antibody IgG1 specific for
15-LO-1—which are h15-LO-1–specific and do not cross-
react with either human 5-LO, 12-LO, or 15-LO-2 or with
mouse 5-LO, but cross-react minimally with mouse 12/15-LO
protein—were used to examine 15-LO-1 protein levels in the
tissues. Previously standardized IHC procedures for tissues
[1,40] were similarly used in this study.
Results
Generation of FLiMP Mice
To study the consequences of aberrant 15-LO-1 expres-
sion on possible prostatic neoplasia development, we used a
flox–stop strategy to target human 15-LO-1 expression
specifically to the mouse prostate. We generated a target-
ing vector CAGloxPCAT–STOPloxPh15-LO-1, as shown in
Figure 1A. In this construct, the CAG promoter drives the
expression of the CAT reporter gene, but the expression of
h15-LO-1 cDNA is blocked due to the poly-A stop signal at the
end of the CAT gene. Subsequent expression of Cre recom-
binase in transgenic animals will excise the reporter cassette
and allow for the expression of the 15-LO-1 transgene.
Three transgenic founder lines were identified and were
named 1857, 1863, and 1868, as shown in Figure 1B. All
three lines demonstrated germline transmission, and were
fertile and viable. The lines were maintained separately on a
C57BL/6 background and were tested for the expression of
the CAT reporter gene in multiple tissues (Figure 2; data for
the 1857 and 1863 lines are not shown). All three lines
demonstrated high levels of CATactivity in all tissues tested.
Mice from each line were also screened for basal h15-LO-1
expression to ensure that there was no leak in the model
system. None of the animals tested demonstrated basal
15-LO-1 expression (data not shown). The 1868 line was
chosen for future experiments and bred to Pb-Cre mice to
generate the FLiMP model. All subsequent experimental
data were produced with this line.
Mice for line 1868 were bred to Pb-Cre mice and tested
for reporter cassette deletion and h15-LO-1 expression. At
8 weeks, the mice became sexually active and their pros-
tates matured. As expected, Cre-mediated recombination on
week 8 resulted in the deletion of the CAT cassette specifi-
cally in the prostate, whereas CATactivity remained identical
to the founder line in all other tissues tested (Figure 2, A
versus B and C). These animals are hereafter referred to
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as FLiMP and are studied in three age ranges: 7 to 10, 18 to
21, and 28 to 35 weeks. FLiMP+/ mice from these matings
were further interbred to obtain homozygous (FLiMP+/+) ani-
mals. In this study, we have examined these mice for pros-
tate phenotypic changes up to 35 weeks (i.e., 8 months) of
age starting on week 7 or week 8.
Expression Patterns of h15-LO-1 in FLiMP Mice
Using qRT-PCR and ELISA (for enzyme activity), we
confirmed the expression of h15-LO-1 mRNA and enzyme
activity in the different prostate lobes of FLiMP mice. Human
15-LO-1 was detected in the prostates of FLiMP+/+ and
FLiMP+/, but neither in wt (control) mice nor in the parental
REAGENT line that was not crossed to Pb-Cre. Although the
levels of h15-LO-1 mRNA were approximately twice in
FLiMP+/+ versus FLiMP+/ (Figure 3, B and C), 15-LO-1 en-
zyme activity was not significantly different in the individual
prostate lobes examined and remained constant at 8, 14, 21,
and 3 weeks of age (data not shown). 15-LO-1 activity in
different regions of the prostate from FLiMP+/+ and FLiMP+/
was normalized for endogenous 12/15-LO (murine ortho-
logue) activity with age-matched nontransgenic littermates.
The 15-LO-1 activities assessed by 13-(S)-HODE for-
mation were also found to be similar in FLiMP+/+ versus
FLiMP+/ (Figure 4).
Relative expression levels of 15-LO-1 mRNA in FLiMP
prostate lobes were in the following order: lateral > ventral >
dorsal > anterior lobe of the prostate (Figure 3). By contrast,
none of the other tissues examined, including the blad-
der, brain, bulbourethral gland, heart, kidneys, large intestine,
small intestine, liver, lungs, seminal vesicles, spleen, stom-
ach, and testes, showed detectable h15-LO-1 mRNA (data
not shown).
Because transgene expression driven by Pb-Cre is ex-
pected to be restricted to luminal epithelial cells of the
prostate in transgenic mice, it was important to determine
the cell type–specific expression pattern of 15-LO-1 in
FLiMP prostates as well. By IHC, we found that, in adult
Figure 1. (A) Map of the pCAG– loxP–CAT– loxP–h15-LO-1 construct. (B) Screening for h15-LO-1 transgenic mouse founders. Lane 1: MW DNA ladder. Lane 2:
H2O control. Lane 3: B6 DNA (negative control). Lane 4: IMR 90 (human cell line). Lane 5: IMR 90 spiked with 0.5 copies/genome, equivalent to h15-LO-1 cDNA.
Lane 6: 1857. Lane 7: 1858. Lane 8: 1859. Lane 9: 1863. Lane 10: 1866. Lane 11: 1867. Lane 12: 1868. Lane 13: 1869. The size of the transgene band is 388 bp,
whereas the size of the human genomic DNA (used as positive control) is 1098 bp.
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FLiMP mouse prostates, h15-LO-1 expression was re-
stricted to luminal epithelial cells (similar to that in human
prostate) and had no detectable immunostaining in either
basal cells or in the stromal compartment (Figure 5, A and B).
Histopathological alterations in FLiMP mice were correlated
with h15-LO-1 expression by IHC. Although cells in hyper-
plastic foci consistently expressed normal levels of mouse
12/15-LO, many cells in the foci that were compatible with
mouse prostatic intraepithelial neoplasia (mPIN) displayed
h15-LO-1 protein expression that was higher than those in
histologically normal areas in FLiMP mice and in prostates of
wt mice. All such mPIN foci showed such increased h15-
LO-1 immunostaining. These foci also showed increased
labeling of Ki-67 with age (Figure 5, C versus D). Hence,
proliferative foci histologically indicative of mPIN were those
focally expressing h15-LO-1, strongly supporting a causative
role for this gene in the mPIN phenotype observed.
Histopathology and IHC Characterization of FLiMP Mice:
Age-Dependent Progressive Prostatic Epithelial Hyperplasia
with Atypia Indicative of mPIN
Blinded histopathology analyses of dorsal prostate (DP)
and lateral prostate (LP) sections of both FLiMP+/+ and
FLiMP+/ mice compared to age-matched wt littermate con-
trol mice demonstrated focal epithelial stratification with gen-
erally mild nuclear atypia. In examined mice, such lesions
were observed at increasing frequency with age, and both
their extent and architectural abnormalities were also noted
to progress with age in FLiMP mice, satisfying the NCI
MMHCC criteria for mPIN (Figures 6 and 7; Table 1).
As noted in Table 1, one of the wt animals showed very
focal andmild proliferation and veryminimal atypia on blinded
review, which was barely, if at all, discernible from normal on
retrospective review. There was no increase in frequency of
proliferation in wild types, compared to that documented in
FLiMP+/ and FLiMP+/+ mice (Table 1). In contrast, the per-
centage of older animals with histopathological evidence
of proliferation with atypia in FLiMP+/ and FLiMP+/+ mice
ranged from 10% to 60% (Table 1). Strikingly, these changes
were progressive, as evidenced by an increase in the per-
centage of FLiMP+/ and FLiMP+/+ mice with proliferation
and atypia in the dorsal and lateral lobes of the prostate
(50–60%) (Table 1).
In the DP, tufting and micropapillary patterns of epithelial
stratification with atypia, corresponding to the most common
architectural patterns of human HGPIN, were noted [32]. In
the proximal DP, tufting foci were noted to be difficult to
distinguish from the prostate of wt mice, which have slightly
greater tufting and architectural complexity in the proximal
ducts, closest to the urethra (Figure 6). However, particu-
larly with increasing age, micropapillary projections of
mildly atypical epithelium were also noted in distal gland
lumens—a morphology quite distinct from the typically flat
cuboidal epithelial lining of wt DP, which has minimal focal
tufting. The nuclei showed mild enlargement, including elon-
gation and hyperchromasia (Figure 6). No foci suspicious
for invasive carcinoma were noted in any section of FLiMP+/
or FLiMP+/+ mice examined, and there were no changes
noted in the stroma of FLiMP mice compared to wt pros-
tates (Figure 6).
Histopathological alterations in the LP were even more
prominent, possibly related to the higher level of h15-LO-1
transgene expression achieved. Compared to the rather
simple flat epithelium in wt LP, FLiMP LP sections showed
progressively severe nuclear stratification, even achieving
focal cribriform architecture (Figure 7). Nuclear atypia was
evident (with some enlargement and hyperchromasia) with
chromatin clumping. The atypia was milder than that seen in
SV40-based models, such as LADY and TRansgenic Ade-
nocarcinoma of Mouse Prostate (TRAMP), and was more in
keeping with degrees seen in other mPIN-containing non–
SV40-based genetically engineered mouse (GEM) models
[32] and human HGPIN.
In some such foci, small nests andmicroacinar formations
were evident beneath the tufting epithelium, in a possibly
thickened surrounding fibromuscular stroma. In some
models that progress to unequivocally more extensive inva-
sive carcinoma, such lesions have been regarded as micro-
invasive carcinoma—a classification within the MMHCC
Pathology Classification [32]. However, in the sections ex-
amined, no such unequivocal foci of invasion into the sur-
rounding looser connective tissues, of an extent indicative of
the classification of invasive carcinoma, were noted. Hence,
Figure 2. CAT screening of tissues from REAGENT transgenic male founder,
and FLiMP+/ and FLiMP+/ transgenic mice at the 8-week time point (n = 4
each). Tissues were collected and used immediately, or frozen and stored at
80jC. Each tissue was individually homogenized and heated, and the
supernatant was used for CAT and protein determination assays. The con-
centration of soluble protein was determined by BioRad protein assay. The
percentage of [14C]chloramphenicol converted to acetylated forms was
determined by scraping individual spots with TLC and by counting in a scin-
tillation counter. CAT activities are expressed as picomoles of acetyl chlo-
ramphenicol generated per minute per milligram of protein, after subtracting
the background for each tissue from control mice that do not express the CAT
gene. Specific activity was calculated as picomoles of product per milligram of
protein per minute. ***P < .01; **P < .05.
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the significance of such potentially microinvasive foci in
FLiMP LP remains to be further elucidated. In addition, in
one LP section of a 35-week-old FLiMP+/+ mouse, a focus
histologically compatible with perineural invasion (PNI) was
noted (Figure 7). In the human prostate, properly defined PNI
is considered pathognomonic for invasive prostate carci-
noma. Similarly, in GEM prostate pathology, PNI is thought
to have similar significance when observed in the setting of
models that have demonstrated progression to unequivocal
invasive prostate carcinoma [32]. Hence, at present, the sig-
nificance of this observation in one FLiMP LP remains to be
more fully elucidated.
No significant histopathological alteration was noted in the
AP of FLiMP+/+ or FLiMP+/ mice up to 35 weeks, perhaps
consistent with the low level of h15-LO-1 expression noted in
the AP. The VPs were not systematically analyzed in the
current study, but foci of pathology similar to that in the LP or
the DP were not noted in the sections examined. The peri-
urethal glands were extensively sampled in FLiMP mice
(present in the majority of animals examined), and no lesions
analogous to hyperplasias, atypical hyperplasias, or carci-
nomas observed in other GEMmodels [32] were noted in any
of the examined animals up to 35 weeks. Likewise, with
equally extensive sampling of the related male accessory tis-
sues of the ampullary glands and seminal vesicles, no lesions
were noted in FLiMP mice up to 35 weeks (data not shown).
Figure 3. Real-time qRT-PCR screening. Extracted RNA were quantitated for mouse -actin and h15-LO-1 from dissected prostate lobes of wt age-matched
C57BL/6 littermate controls (A) compared to hemizygous (B) and homozygous (C) FLiMP mice. RNA from dissected dorsolateral, anterior, and ventral prostate
lobes, each from three transgenic C57BL/6 FLiMP+/ (hemizygous) and FLiMP+/+ (homozygous) mice at 10 weeks of age, were compared to control RNA similarly
extracted from wt mice. Real-time quantitations were performed using the iQ5 Real-Time PCR Detection System, as described in the Materials and Methods
section. A comparative relative expression level of h15-LO-1 mRNA in different prostate lobes of homozygous (5) and hemizygous (52) mice is represented (D).
Fluorescence threshold values were calculated using the system software. (x) 15-LO-1 anterior; (n) 15-LO-1 lateral; (E) 15-LO-1 ventral; () 15-LO-1 dorsal; (*)
-actin anterior; (.) -actin lateral; (+) -actin ventral; () -actin dorsal.
Figure 4. 13-HODE levels in tissues, as a measure of 15-LO-1 activity, were
examined using commercially available ELISA plates, as described in Mate-
rials and Methods section. Concentrations of 13-(S)-HODE were represented
as micrograms per milliliter per gram of tissue after normalizing for the endog-
enous murine 12/15-LO protein similarly extracted from transgenic wt litter-
mate control samples. Proteins extracted from dissected dorsolateral (#),
ventral (5), and anterior (n) prostate lobes, each from three transgenic
C57BL/6, FLiMP+/ (A), and FLiMP+/+ (B) mice at 8, 14, 21, and 32 weeks of
age, were compared to age-matched nontransgenic C57BL/6 littermate wt
control proteins that were similarly extracted and pooled.
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Discussion
GEM models of PCa have been developed by either in-
troducing SV40 T-antigen or knocking out tumor-suppressor
genes [32,41]. A GEM model of a disease represents a vital
way by which to study both the pathobiology and the effect
of new therapeutic strategies. Validation criteria include a
comparison of histopathological, genetic, biochemical, and
natural history features of the GEM model with known
aspects of human PCa, including relevant changes at dif-
ferent stages of progression of this complex and heteroge-
neous neoplasm [32,42–44]. Animal models can provide an
essential resource for testing the efficacy of potential chemo-
preventive agents [45]. Historically, xenograft models, which
use injection or implantation of established tumor cell lines
into immunodeficient host mice, have been widely used for
chemoprevention studies. Although these models offer many
advantages, including ease of experimental manipulation
and short time frame for analyses, there are several notable
drawbacks to their use for chemoprevention studies. Firstly,
the cell lines used for xenografts are typically highly trans-
formed and have been selected for growth in cell cul-
ture, which obviously does not recapitulate the natural
progression of cancer, particularly in the early stages of the
disease. Secondly, the use of immunodeficient mice elimi-
nates an intact host immune response, which is likely to play
an important role in prostate carcinogenesis [46].
Precise molecular events associated with the initiation of
prostate carcinoma are unknown. PIN is widely regarded as
a precursor of human PCa [47,48]. Our results have identi-
fied a new and important role for 15-LO-1 in the initiation
Figure 5. Representative immunostaining of dorsolateral prostate (DLP) and ventral prostate lobes from homozygous (B and E) and hemizygous (C and F) FLiMP
mice compared to wt littermate controls (A and D) at 28 weeks (A) and 35 weeks (B) with polyclonal antibody for h15-LO-1 (original magnification, 100). Similarly,
representative immunostaining of the same mice, as described above at 28 weeks (C) and 35 weeks (D), with polyclonal antibody for Ki-67 (original magnification,
100) is shown by arrows.
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of PCa. Previous studies using well-characterized mouse
models of PCa support a role for 15-LO-1 in cancer patho-
biology [40,49]. We observed a robust expression of the
murine orthologue of human 15-LO-1 (12/15-LO) in samples
of both HGPIN and lung metastasis from TRAMP mice [40].
This observation also holds true for the large Pb T antigen
transgenic PCa mouse model [49]. Therefore, we felt that it
was logical to extend these results by independently analyz-
ing the effect of the overexpression of 15-LO-1 on a novel
transgenic system. Our present study, characterizing the
FLiMP transgenic mouse model, has confirmed that it dem-
onstrates a phenotype that is consistent with human HGPIN,
and a close association between aging and progression to
neoplasia. As 15-LO-1 also plays an essential role in the de-
velopment and differentiation of the prostatic epithelium, it
provides an important link between development and
carcinogenesis in the prostate gland. Several groups have
previously reported another gene, called Nkx3.1, that plays
a role in the development of PIN as a tumor-suppressor gene
[50–54]. This was demonstrated by conventional gene
Figure 6. Representative histopathology of dorsal prostate (DP) sections of FLiMP mice. (A) Intermediate magnification of a 14-week-old FLiMP+/mouse showing
focal epithelial stratification and small cribriform architecture within a normal-sized proximal duct lumen (arrowhead). Urethra/periurethral ducts on the top left (*).
Seminal vesicle lumen on the bottom right (SV). More distal DP portions, with a usually thin rim of fibromuscular stroma surrounding individual gland lumens, are
shown on the left (DP). (B) Higher magnification of the same 14-week-old FLiMP+/ mouse, showing mild epithelial stratification with minimal nuclear atypia in
proximal DP lumen, with focal mitotic figures (arrowhead). (C) Proximal DP area of wt mouse. Urethral lumen on the top left (*). Seminal vesicle on the top right
(SV). Normal proximal duct lumens can have more epithelial stratification and architectural complexity (arrowheads) than more distal DP lumens, making the
distinction of pathological epithelial proliferations without prominent atypia in these locations difficult to distinguish from the normal wt prostate histologic spectrum.
(D) Focal epithelial proliferation with minimal to mild atypia in distal DP portions of a 28-week-old FLiMP+/ mouse. Tufting and micropapillary architecture greater
than the usual limited tufting of wt DP are evident, architecturally similar to those that are common in human PIN. Scattered apoptotic bodies were noted (arrows).
(E) Intermediate magnification of DP in a 28-week-old FLiMP+/+ mouse showing focal epithelial stratification with tufting in multiple lumens (arrowheads). A ganglion
(typical of loose stroma surrounding the DLP) is noted on the left (*). (F) Higher magnification of the DP of the same 28-week-old FLiMP+/+ mouse as in (E).
Epithelial proliferation, manifested as stratification and tufting, with mild atypia is noted in multiple foci (arrowheads). The architecture is quite distinct from the
cuboidal epithelium, with minimal focal tufting in wt DP. (G) Proximal DP of a 35-week-old FLiMP+/+ mouse showing epithelial tufting, with mild atypia, in multiple
lumens (arrowheads). An adjacent lumen shows focal microacinar spaces or signet ring– like cells within the luminal epithelium or the signet ring (arrow). (H) Distal
DP of the same 35-week-old FLiMP+/+ mouse showing tufting and micropapillary epithelial stratification with mild atypia. The focality and progression (in extent) of
such epithelial proliferations with some nuclear atypia are compatible with definitions of mPIN (H&E staining). (B, D, F, G, H) Original magnification, 400. (A, C, E)
Original magnification, 200.
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knockout techniques using Nkx3.1–deficient mice. Similar to
our study with FLiMP, Nkx3.1 knockout animals also de-
veloped prostatic epithelial neoplasia in the setting of de-
velopmental abnormalities of the prostate. However, FLiMP
mice display mPIN-like lesions after 5 months, compared to
Nkx3.1 knockout mice that develop mPIN only after 1 year.
The lesions that developed in FLiMP mice resemble
human PIN in several respects. In addition to histopatho-
logical similarities, the lesions showed a similar pattern of
Ki-67 expression and partial disruption of basal cells, as seen
with human PIN lesions. Thus, conditional expression of
15-LO-1 in adult mice predicted the consequences in the
Figure 7. Histopathology of the lateral prostate (LP) of FLiMP Mice. (A) Intermediate magnification showing normal LP (right) and DP (left). wt LP contains duct
lumens with simple cuboidal to columnar epithelium, with basilar nuclei and typically clear to lightly granular eosinophilic cytoplasm. There is usually no tufting to
minimal tufting, such that the luminal epithelial lining is flat or smooth. A thin rim of fibromuscular stroma surrounds the epithelium. A ganglion is noted in mid-
bottom, in the loose surrounding stroma. (B) The LP of a 28-week-old FLiMP+/ mouse showing focal epithelial proliferation, involving a single gland profile at the
bottom center (arrowhead). Residual normal-appearing LP gland lumens are present (LP, center), and a portion of DP is shown on the top left. (C) Higher
magnification of a 28-week-old FLiMP+/ mouse LP is shown in (B). The gland lumen shown is extensively involved with epithelial proliferation, with cell
stratification seen in areas with tufting and micropapillary architecture (arrowheads). Intraluminal micropapillary proliferation appears to contain a central core of
vascularized fibromuscular stroma. There is mild nuclear atypia, with nuclear enlargement/elongation and hyperchromasia. An area of epithelium within the
fibromuscular stroma of this particular gland profile (right-hand side, about 4 o’clock) was interpreted as due to tangential sectioning and is not indicative of
invasion. The focality of the lesion is evident by comparison to residual normal-appearing LP gland profiles (arrow, top left). (D) The LP of a 28-week-old FLiMP+/+
mouse, showing areas of tufting of the epithelium into the gland lumen (arrowheads). In some such foci (as illustrated in focus at the right arrowhead), there were
microacinar spaces within the fibromuscular stroma under areas of the tufting epithelium. In some GEM models, these types of lesions have been classified as
microinvasive carcinoma. The significance of these foci in the FLiMP model remains to be further characterized, as more unequivocal areas of invasive carcinoma,
including extension through fibromuscular stroma into surrounding loose connective tissues, have not been noted. (E) Intermediate magnification of the LP of a
different 28-week-old FLiMP+/+ mouse showing two gland profiles that are prominently involved in epithelial proliferation with mild atypia (arrowheads). Residual
more-normal-appearing LP glands are also evident (arrow, center). (F) Higher magnification of one LP region shown in (E), from a 28-week-old FLiMP+/+ mouse.
Epithelial proliferation takes the form of micropapillary luminal projections and even cribriform architecture (arrowheads). There are nuclear stratification and mild
nuclear atypia, with enlargement/elongation and hyperchromasia. (G) The LP of a 35-week-old FLiMP+/+ mouse showing two adjacent gland profiles with epithelial
proliferation with atypia, manifested as prominent stratification and tufting into the gland lumens (arrowheads). On focus on the top right, the area of epithelial tufting
is accompanied by single cells, small nests, and microacini of similar cells within a thickened fibromuscular stroma (thin strips of stroma that are evident between
luminal facing cells and underlying nests), strongly raising the consideration of microinvasion (arrow). Areas of more unequivocal invasion into surrounding looser
stroma were not noted. A ganglion is noted on top (*), typical of the DLP. The presence of progressively more prominent atypical epithelial proliferation
(e.g., compare lesions in G versus D) is diagnostic of mPIN, according to a standardized NCI GEM prostate pathology classification scheme. (H) The LP of a
different 35-week-old FLiMP+/+ mouse, showing a focus suspicious for PNI (arrowhead), with nests of epithelium within the nerve/ganglion (*).
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initiation of PCa in humans. All of the FLiMP+/ and FLiMP+/+
mice that we studied developed focal epithelial hyperplasia.
In a subset of these animals, PIN-like lesions were also
observed, and these PIN lesions showed high 15-LO-1
expression, as determined by IHC. The precise mechanism
of an aberrant overexpression of 15-LO-1 in PIN and PCa is
presently unclear, but may involve epigenetic mechanisms
such as promoter hypermethylation [27], leading to over-
expression of 15-LO-1. This is particularly intriguing, as
studies have independently suggested a positive correlation
between high–N-6 fat diets [55–57] and methylation in
human prostate tumors [47,58].
We have shown that, in both mature human and mouse
prostates, 15-LO-1 expression is limited to the luminal epi-
thelial cell layer. Our results suggest that aberrant expression
of 15-LO-1 in luminal cells is permissive of dedifferentiation
and reentry into the cell cycle, subsequently leading to the
development of PIN. The mechanism by which the 15-LO-1
and LA metabolic product 13-HODE engages the cell cycle
machinery in prostate cells in different developmental stages
of the prostate gland and in carcinoma is an interesting subject
that warrants further investigation. Additional unanswered
questions include whether PIN lesions in conditional FLiMP
transgenic mice can progress to invasive carcinoma and
metastaseswith aging or by other hormonal, dietary, or genetic
manipulations. Further studies, which include variables such
as aging for longer periods, and high N-6 fatty acid dietary
studies are in progress to address this question. Therefore,
the FLiMP mouse model provides a novel model system for
studying the PIN stage of PCa development because it reca-
pitulates a much earlier PIN phenotype than that observed in
NKX3.1 conditional knockout mice.
Transgenic mice can provide valuable models for chemo-
prevention studies. However, it was only recently that the
community of PCa researchers began to accept the idea of
using transgenic and mutant mice to study human PCa. In
previous years, there has been a great deal of skepticism
regarding the relevance of such models, based on significant
anatomic and histologic differences between the mouse pros-
tate and the human prostate, and the low incidence of spon-
taneous PCa in mice (discussed in Abate-Shen and Shen
[59,60]). However, it is becoming increasingly clear that the
molecular mechanisms underlying PCa progression are highly
conserved between mice and humans [50,60–62]. ‘‘First-
generation’’ mouse models of PCa, which were pioneered by
Greenberg, Matusik, and others, were based on the expres-
sion of SV40 oncogenes on the prostatic epithelium under the
control of promoters that display prostate specificity, such as
that for the Pb gene (reviewed inWu et al. [34] and Huss et al.
[61]). These transgenic mice, particularly the well-studied
TRAMP and LADY models, undergo a series of progressive
changes from PIN to invasive cancer and metastases with rel-
atively short latency (2–6 months) and have been valuable
for molecular analyses of prostate carcinogenesis. In addi-
tion, these models have been used for chemoprevention
studies to test the efficacy of certain dietary and pharma-
ceutical agents [63–65]. We have taken a complementary
approach by generating a ‘‘second-generation’’ FLiMP trans-
genic mouse model by overexpressing the human 15-LO-1
enzyme, which is known to be relevant for human PCa.
Some other relevant second-generation transgenic and mu-
tant mice include Nkx3.1, Pten, and p27kip1 [34,51–53,
66–70]. Importantly, histopathological and molecular analy-
ses of thesemutantmice and our transgenic FLiMPmice have
validated their similarity to human PCa.
It is conceivable that 15-LO-1 enzyme activity, in concor-
dance with the acquisition of Nkx3.1 mutation, could be
sufficient to drive prostate epithelial transformation (i.e.,
PIN progression to PCa in vivo). An advantage to this sys-
tem, which we feel is particularly relevant for PCa, is that the
double transgenic (compound) model can mimic two natu-
rally occurring early events in PCa development that other-
wise are individually insufficient to cause progression to
carcinoma. Thus, 15-LO-1 is clearly necessary but not suf-
ficient in itself to cause PCa, supporting the multihit hypoth-
esis. A study with FLiMP+/+, Nkx3.1/ compound mouse
model will provide relevant insights for PCa progression,
especially initiation events leading to PCa. Therefore, the
Table 1. Histochemistry and Pathological Description in Prostates of Aging FLiMP and wt Littermate Control Mice.
Mice Lobe 7–21 weeks 24–28 weeks 35 weeks
Histology* (n) Proliferation
with Atypiay [n (%)]
Histology* (n) Proliferation
with Atypiay [n (%)]
Histology* (n) Proliferation with
Atypiay [n (%)]
wt DP 10 1z (10) 2 0 6 0 (0)
LP 9 1z (10) 2 0 6 0 (0)
+/ DP 8 2 (25) 10 3 (30) 2 1 (50)
LP 9 1 (11) 9 3 (25) 2 1 (50)
+/+ DP 7 1 (14) 9 5 (55) 9 5 (56)
LP 7 1 (14) 8 3 (38) 5 3 (60)
*Number of mice for which extensive sections of individual indicated lobes were present for blinded histologic review.
yNumber/percent of mice with any degree of focal proliferation and any degree of nuclear atypia. The objective of the table is to document an increase in the
number/percent of mice with proliferation and atypia. The numbers do not take into account the severity of these changes (i.e., extent of abnormalities within given
mice, degree of proliferation within foci, and severity of nuclear atypia). The increase in the severity of the lesions with time is documented in the text and in the
figures.
zVery focal and mild proliferation and very minimal atypia on blinded review, which are barely, if at all, discernible from normal on retrospective review; no increase
in the frequency of proliferation was noted in wt mice versus FLiMP+/ and FLiMP+/+ mice. Lesions, as noted in 24- to 35-week-old FLiMP mice and as described in
the text and in Figures 6 and 7, were not seen in wt mice.
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FLiMP mouse model is likely to provide extensive data on
early events correlating to PIN that are essential for PCa
initiation and for the development of a therapeutic model for
an effective early treatment of PCa.
To our knowledge, this is the first study to use a transgenic
mouse model (FLiMP) to demonstrate a role of h15-LO-1 in
the development of prostate lesions that resemble mPIN.
Thus, 15-LO-1 has an important role in regulating progres-
sion from normal to PIN. The use of the FLiMP mouse model
will assist investigators in gaining better understanding,
particularly regarding the cooperative effects of multiple genes
on PCa initiation and cancer predisposition, as 15-LO-1 ex-
pression and function may not be sufficient to cause PCa in
mice at 5 months of age.
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